ADAR1 Capital Management LLC Buys Shares of 1,565,029 Fulcrum Therapeutics, Inc. $FULC

Key Points

• ADAR1 Capital Management acquired 1,565,029 shares of Fulcrum Therapeutics, worth approximately $5.7 million, giving it a 2.05% stake. Institutional investors collectively own 89.83% of the company.
• Analysts have recently downgraded the stock, with Fulcrum receiving a consensus rating of “Reduce” and an average price target of $8.20. The company also missed quarterly EPS estimates, reporting a loss of $0.34 per share versus expectations of $0.24.
• FULC opened at $3.86, near the lower end of its $2.83–$15.74 one-year trading range. The clinical-stage biotech is developing precision medicines, including candidates for sickle cell disease, beta-thalassemia, and facioscapulohumeral muscular dystrophy.

ADAR1 Capital Management LLC purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,565,029 shares of the company's stock, valued at approximately $5,728,000. ADAR1 Capital Management LLC owned about 2.05% of Fulcrum Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of FULC. Cubist Systematic Strategies LLC acquired a new stake in shares of Fulcrum Therapeutics during the first quarter worth $164,000. Jane Street Group LLC lifted its position in Fulcrum Therapeutics by 62.1% during the first quarter. Jane Street Group LLC now owns 117,816 shares of the company's stock worth $339,000 after buying an additional 45,157 shares during the period. Creative Planning purchased a new position in Fulcrum Therapeutics during the second quarter worth about $117,000. Legal & General Group Plc lifted its position in Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company's stock worth $120,000 after buying an additional 12,173 shares during the period. Finally, American Century Companies Inc. boosted its stake in Fulcrum Therapeutics by 7.0% in the 2nd quarter. American Century Companies Inc. now owns 132,349 shares of the company's stock worth $911,000 after buying an additional 8,638 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on FULC shares. Wall Street Zen upgraded Fulcrum Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, May 2nd. Piper Sandler lowered shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating and set a $3.00 price objective on the stock. in a report on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and set a $3.00 target price on the stock. in a research report on Tuesday, June 2nd. Citigroup downgraded shares of Fulcrum Therapeutics from an "underperform" rating to an "underweight" rating in a report on Tuesday, June 2nd. Finally, JPMorgan Chase & Co. lowered shares of Fulcrum Therapeutics from an "overweight" rating to an "underweight" rating in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of "Reduce" and a consensus price target of $8.20.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $3.86 on Wednesday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.83 and a 1-year high of $15.74. The firm has a market capitalization of $294.52 million, a P/E ratio of -3.19 and a beta of 3.05. The business's 50-day simple moving average is $3.72 and its 200-day simple moving average is $6.10.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). On average, equities research analysts expect that Fulcrum Therapeutics, Inc. will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, Director Alan Ezekowitz sold 18,000 shares of the company's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director directly owned 10,927 shares of the company's stock, valued at approximately $39,883.55. This represents a 62.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.30% of the company's stock.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.